Healthcare
Eli Lilly and Company (LLY)
Eli Lilly and Company stock analysis and opportunity scoring
$1152.44
↑ +1.28%
Eli Lilly and Company (LLY) at a glance
Eli Lilly and Company (LLY) is a publicly traded company in the Healthcare - Drug Manufacturers - General sector tracked by MKD Intelligence.
LLY last traded at $1255.40 as of 2026-09-19.
MKD Intelligence assigns LLY a composite opportunity score of 55 out of 100, indicating mixed conditions across trend, momentum and volume factors.
The risk score for LLY is 28 out of 100 (low), where a higher number means greater expected volatility.
Price History
High
$1255.40
Low
$1115.70
Period
Sep 17 - Aug 21 (19d)
Hover for details • Scroll to zoom • Drag to pan • Double-click to reset
Recent News
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future - The New York Times
The New York Times · Sep 1
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future - The New York Times
The New York Times · Sep 1
Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026 - Endpoints News
Endpoints News · Aug 31
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies - Fierce Biotech
Fierce Biotech · Aug 31
Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion - WSJ
WSJ · Aug 31
Upcoming Events
Data as of Sep 19
This platform provides market intelligence and educational information only. It does not constitute financial advice, and no information presented should be interpreted as a recommendation to buy, sell, or hold any security. Past performance and historical patterns do not guarantee future results.